Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration

Journal of Clinical Psychiatry

Volumn 73, Issue 6, 2012, Pages 856-864

  Khin, Ni A ^a   Chen, Yeh Fong ^a   Yang, Yang ^a,b   Yang, Peiling ^a   Laughren, Thomas P ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b SANTEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; PLACEBO;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DSM-III; DSM-IV; EXPLORATORY ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NORTH AMERICA; PATIENT COMPLIANCE; PLACEBO EFFECT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; SCHIZOPHRENIA; STUDY DESIGN; TREATMENT OUTCOME;

EID: 84863550159     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11r07539     Document Type: Article

References (33)

1. Karlberg JPE. Trends in disease focus of drug development. Nat Rev Drug Discov. 2008;7(8):639-640. doi:10.1038/nrd2618 PubMed
2. Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system: Epidemiologic Catchment Area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993;50(2):85-94. doi:10.101/archpsyc.193.01820140701 PubMed (Pubitemid 23059313)
3. Jablensky A. The 100-year epidemiology of schizophrenia. Schizophr Res. 1997;28(2-3):111-125. doi:10.1016/S0920-964(97)85354-6 PubMed (Pubitemid 28055660)
4. Mueser KT, McGurk SR. Schizophrenia. Lancet. 2004;363(9426):2063-2072. doi:10.1016/S0140-6736(04)16458-1 PubMed (Pubitemid 38781110)
5. Laughren TP. The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective. Eur Psychiatry. 2001;16(7):418-423. doi:10.1016/S0924-938(01)060-9 PubMed (Pubitemid 33101277)
6. Leucht S, Arbter D, Engel RR, et al. How effective are second-generation antipsychotic drugs? a meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14(4):429-447. doi:10.1038/sj.mp.402136 PubMed
7. Kemp AS, Schooler NR, Kalali AH, et al. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull. 2010;36(3):504-509. doi:10.1093/schbul/sbn10 PubMed
8. Chen YF, Wang SJ, Khin NA, et al. Trial design issues and treatment effect modeling in multi-regional schizophrenia trials. Pharm Stat. 2010;9(3):217-229. doi:10.102/pst.439 PubMed
9. Thiers FA, Sinskey AJ, Berndt ER. Trends in the globalization of clinical trials. Nat Rev Drug Discov. 2008;7(1):13-14. doi:10.1038/nrd241
10. US Department of Health and Human Services. Code of Federal Regulations, Title 21-Food and Drugs, Part 314, Applications for FDA Approval to Market a New Drug. 21 CFR Part 314.106: Foreign Data. http://ecfr.gpoaccess.gov/cgi/t/text/ text-idx?c=ecfr;sid=c4683e3b7214a3bef6f567bc293ff57c;rgn=div5;view=text;node= 21%3A5.0.1.1.4;idno=21;cc=ecfr#21:5.0.1.1.4.4.1.7. Revised April 1, 2011. Updated July 29, 2011. Accessed August 2, 2011.
11. US Department of Health and Human Services. Code of Federal Regulations, Title 21-Food and Drugs, Part 312, Investigational New Drug Applications. 21 CFR 312.120: Foreign Clinical Studies Not Conducted Under an IND. http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid= d199e7693c50a9bb0de86c4b652807c7&rgn=div8&view=text&node=21:5.0.1.1. 3.6.1.2&idno=21. Revised April 1, 2011. Updated September 7, 2011. Accessed Sept 9, 2011.
12. Topic ICH. E5 (R1). Ethnic Factors in the Acceptability of Foreign Clinical Data. CPMP/ICH/289/95. http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500002842.pdf. Published September 1998. Accessed August 3, 2011.
13. Topic ICH. E6 (R1). Good Clinical Practice. Finalized Guideline: May 1996. http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/ good-clinical-practice.html. Accessed October 27, 2011.
14. Temple R. Use of non-US data in NDAs. Special session: Regulatory Considerations of Using Non-US Data in NDAs: Focus on Efficacy, Safety and Clinical Pharmacology. Presented at the Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; March 20, 2009; Washington, DC. http://www.ascpt.org/Portals/8/docs/Meetings/2009%20Annual%20Meeting/Friday/ Regulatory%20Considerations.pdf. Accessed March 10, 2011.
15. Committee for Medicinal Products for Human Use (CHMP). European Medicines Agency (EMEA): reflection paper on the extrapolation of results from clinical studies conducted outside Europe to the EU-population. EMEA/CHMP/EWP/692702/ 2008: 1-7. http://www.ema. europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/11/WC500013468.pdf. Published February 19, 2009. Updated October 22, 2009. Accessed March 10, 2011.
16. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. PubMed (Pubitemid 18039085)
17. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Res. 1988;23(1):99-110. doi:10.1016/0165-1781(8)9038-8 PubMed
18. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
19. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York, NY: Springer-Verlag; 2000.
20. Khin NA, Chen YF, Yang Y, et al. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry. 2011;72(4):464-472. doi:10.408/JCP.10m06191 PubMed
21. Karagianis J, Novick D, Pecenak J, et al. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract. 2009;63(11):1578-1588. doi:10.1/j.1742-1241.209.02191.x PubMed
22. Trivedi MH, Rush H. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacology. 1994;11(1):33-43. PubMed (Pubitemid 24277736)
23. Faries DE, Heiligenstein JH, Tollefson GD, et al. The double-blind variable placebo lead-in period: results from two antidepressant clinical trials. J Clin Psychopharmacol. 2001;21(6):561-568. doi:10.1097/04714-20120-04 PubMed (Pubitemid 33116654)
24. Lee S, Walker JR, Jakul L, et al. Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? a meta-analytic evaluation. Depress Anxiety. 2004;19(1):10-19. doi:10.102/da.10134 PubMed (Pubitemid 38294604)
25. Chen YF, Yang Y, Hung HMJ, et al. Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials. Contemp Clin Trials. 2011;32(4):592-604. doi:10.1016/j.ct.201.04.06 PubMed
26. Fava M, Evins AE, Dorer DJ, et al. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72(3):115-127. doi:10.159/069738 PubMed (Pubitemid 36469860)
27. Tamura RN, Huang X. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials. Clin Trials. 2007;4(4):309-317. doi:10.17/174074507081217 PubMed (Pubitemid 47572263)
28. Landin R, DeBrota DJ, DeVries TA, et al. The impact of restrictive entry criterion during the placebo lead-in period. Biometrics. 2000;56(1):271-278. doi:10.1/j.06-341X.20.0271.x PubMed (Pubitemid 30165119)
29. Leucht S, Heres S, Hamann J, et al. Methodological issues in current antipsychotic drug trials. Schizophr Bull. 2008;34(2):275-285. doi:10.1093/schbul/sbm159 PubMed (Pubitemid 351323339)
30. Rabinowitz J, Levine SZ, Barkai O, et al. Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Schizophr Bull. 2009;35(4):775-788. doi:10.1093/schbul/sbn05 PubMed
31. Kobak KA, Kane JM, Thase ME, et al. Why do clinical trials fail? the problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol. 2007;27(1):1-5. doi:10.1097/JCP.0b013e31802eb4b7 PubMed (Pubitemid 46105756)
32. Shen J, Kobak KA, Zhao Y, et al. Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia. J Clin Psychopharmacol. 2008;28(6):691-693. doi:10.1097/JCP.0b013e31818c9ba3 PubMed
33. Liu KS, Snavely DB, Ball WA, et al. Is bigger better for depression trials? J Psychiatr Res. 2008;42(8):622-630. doi:10.1016/j.jpsychires.207.07.03 (Pubitemid 351626061)